Everything below concerns Phase 3 trial. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
=== Mayor of San Salvador === In August 2014, Bukele announced that he would seek election as mayor of San Salvador in the 2015 elections. His candidacy was confirmed by FMLN secretary-general Medardo González on 19 August 2014. Bukele delegated administration of Nuevo Cuscatlán to council member Michelle Sol in February 2015 to focus on his campaign. During his campaign, which was supported by the Salvadoran Progressive Party, FMLN party leadership called Bukele the party's "crown jewel" ("joya de la corona"). Bukele's campaign used catchphrases such as "we have to change history" ("tenemos que cambiar la historia") and "together we will go forward" ("juntos saldremos adelante") to rally support from young voters. His primary opponent was Edwin Zamora, a businessman and Legislative Assembly deputy from ARENA. Bukele led Zamora in opinion polls before the election. He defeated Zamora with 50.38 percent of the vote on 1 March 2015, and took office on 1 May. Bukele appointed a cousin, Hassan, and his half-brother Yamil to administrative positions on the San Salvador municipal council. The appointments were criticized by ARENA and FMLN politicians.
=== Barney Calhoun === Barney Calhoun is the player character in Half-Life: Blue Shift and a major character in Half-Life 2 as well as Half-Life 2: Episode One. Michael Shapiro provided Barney's voice in the games of the Half-Life series. Scott Lynch, Valve's chief operating officer, lent his face to the game for use in-game as Barney in Half-Life 2. Barney's name stemmed from the earlier alpha versions of Half-Life in which the model for the security guards held a resemblance to actor Don Knotts, inspiring comparisons with Knotts's character Barney Fife from The Andy Griffith Show, which in the United States has long been a disparaging term for an inept policeman or security guard. Initially, the "Barneys" were intended to be hostile NPCs who would attack the player. In Half-Life: Blue Shift, the playable Barney progresses through Black Mesa to escape the events of the Resonance Cascade and is able to do so, in contrast to Gordon Freeman and Adrian Shephard, who are held in stasis. In Half-Life 2, Barney works as a mole for the Lambda Resistance in the Combine Civil Protection Forces. He provides the player information in the first chapter, leading him to Kleiner and Vance, and in the end of the second chapter, he provides the player with his crowbar. The fact that Barney owes Gordon Freeman a beer is a running gag in the series.
== Puberty onset == Puberty is preceded by adrenarche, marking an increase of adrenal androgen production between ages 6–10. Adrenarche is sometimes accompanied by the early appearance of axillary and pubic hair. The first androgenic hair resulting from adrenarche can be also transient and disappear before the onset of true puberty. The onset of puberty is associated with high GnRH pulsing, which precedes the rise in sex hormones, LH and FSH. Exogenous GnRH pulses cause the onset of puberty. Brain tumors which increase GnRH output may also lead to premature puberty. The cause of the GnRH rise is unknown. Leptin might be the cause of the GnRH rise. Leptin has receptors in the hypothalamus which synthesizes GnRH. Individuals who are deficient in leptin fail to initiate puberty. The levels of leptin increase with the onset of puberty, and then decline to adult levels when puberty is completed. The rise in GnRH might also be caused by genetics. A study discovered that a mutation in genes encoding both neurokinin B as well as the neurokinin B receptor can alter the timing of puberty. The researchers hypothesized that neurokinin B might play a role in regulating the secretion of kisspeptin, a compound responsible for triggering direct release of GnRH as well as indirect release of LH and FSH.
All work in Berlin ceased by July. Hahn and his family moved to the house of a textile manufacturer there. Life became precarious for those married to Jewish women. One was Philipp Hoernes, a chemist working for Auergesellschaft, the firm that mined the uranium ore used by the project. After the firm let him go in 1944, Hoernes faced being conscripted for forced labour. At the age of 60, it was doubtful that he would survive. Hahn and Nikolaus Riehl arranged for Hoernes to work at the KWIC, claiming that his work was essential to the uranium project and that uranium was highly toxic, making it hard to find people to work with it. Hahn was aware that uranium ore was fairly safe in the laboratory and could be mined safely using the correct equipment and procedures, but the 2,000 female slave labourers from the Sachsenhausen concentration camp who mined it in Oranienburg suffered agonising deaths because their Nazi slavedrivers wilfully neglected their safety. Another physicist with a Jewish wife was Heinrich Rausch von Traubenberg. Hahn certified that his work was important to the war effort, and that his wife Maria, who had a doctorate in physics, was required as his assistant. After he died on 19 September 1944, Maria faced being sent to a concentration camp. Hahn mounted a lobbying campaign to get her released, but to no avail, and she was sent to the Theresienstadt Ghetto in January 1945. She survived the war, and was reunited with her daughters in England.
Sources: en.wikipedia.org
(Two supernormal clutches of eight eggs and one of nine have been documented. One egg in one of the eight-egg clutches hatched as did one egg in the nine-egg clutch.) The average egg size is 32 mm × 29 mm (1.3 in × 1.1 in), 10% larger than average for birds of its body size. The eggs are white to cream in color with brown or gray splotching. Incubation usually lasts 30 days and is mainly the responsibility of the female, although the male incubates 15–20% of the time. Eggs that are lost are typically replaced in 11–12 days. Hatching takes place over three to four days. Hatchlings are altricial, and are only able to sit up after five days. They grow rapidly, reaching an adult weight after 16–17 days. After 28–31 days, their wings have developed and they are able to leave the nest. The young adult kestrels may breed from a year old, and the species has approximately a three to five-year life expectancy in the wild. In ecological terms, the reproductive pattern of the American kestrel leans towards a small bird "r selection" strategy. In r/K selection theory, selective pressures are hypothesized to drive evolution in one of two generalized directions: r or K selection. R-selected species are those that place an emphasis on a high growth rate, typically exploiting less-crowded ecological niches, and produce many offspring, each of which has a relatively low probability of surviving to adulthood (i.e., high r, low K).
== Influences and philosophy == Walker used Team Fortress 2 updates to research what additional features are and aren't popular. The results of which he has used for the development of Dota 2, as well as for later Team Fortress 2 updates. Walker also stated that he cannot guarantee that he would keep working on Team Fortress 2 indefinitely and that at some point, he will move on to a new project. Walker believes in the importance of communication between players and developers of modern PC games, stating that "being close to your customers – being able to talk directly to your customers – is valuable." In his experience, successful multiplayer games "innovate in gameplay both on release, but also over time post-release, and that those innovations are significant and of interest to customers." Walker is not worried about video game piracy, stating that to fight piracy, he is "looking at the things that pirates are providing and asking [himself] how [he] can provide something better than that." By releasing frequent updates of his games after launch, he constantly improves on his games in a way that pirates could not keep up with. Walker is a supporter of the free-to-play model, as he says that the model supports a wider variety of customers, including those with "very little money," and that such a variety of players results in greater opportunities for richer experiences.
Ethinylestradiol, conjugated estrogens, and other non-bioidentical estrogens largely stopped being used in transgender women in favor of estradiol starting around 2000 due to their greater risks of blood clots and cardiovascular issues. In modern times, hormone therapy in transgender women is usually done with the combination of an estrogen and an antiandrogen. In some places however, such as Japan, use of antiandrogens is uncommon, and estrogen monotherapy, for instance with high-dose injectable estradiol esters, is still frequently used.
== Epidemiology == In the United States, hyperthyroidism affects about 1.2% of the population. About half of these cases have obvious symptoms, while the other half do not. It occurs between two and ten times more often in women. The disease is more common in those over the age of 60 years. Subclinical hyperthyroidism modestly increases the risk of cognitive impairment and dementia.
== Efficacy == There is currently no standardized form of dry needling. There is a general scarcity of extensive research in the field. Many studies published about dry needling are not randomized, contain small sample sizes, and have high dropout rates. A review recommended the usage of dry needling, compared to sham or placebo, for decreasing pain immediately after treatment and at 4 weeks in patients with upper quarter myofascial pain syndrome. However, the authors caution that "the limited number of studies performed to date, combined with methodological flaws in many of the studies, prompts caution in interpreting the results of the meta-analysis performed". Similarly, a second review of dry needling found insufficient high-quality evidence for the use of direct dry needling for short and long-term pain and disability reduction in patients with musculoskeletal pain syndromes. The same review reported that robust evidence validating the clinical diagnostic criteria for trigger point identification or diagnosis is lacking and that high-quality studies demonstrate that manual examination for the identification and localization of a trigger point is neither valid nor reliable between examiners.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.